In IBD, since this phenomenon is not associated with systematic loss of response, and that TNF-α reservoir is admitted to be both circulating and expressed on intestine inflammatory cells (monocytes, macrophages) [12,13,14], it may be hypothesized that infliximab’s effect is related to its binding to TNF-α in a ‘deep’ compartment. Here, TNF is linked to inflammatory bowel disease.